Inavolisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.679
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Inavolisib. Strongest target: DNA_PK at 24.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DNA_PK | 24.2% | 75.8% |
| 2 | LRRK2 | 21.6% | 78.4% |
| 3 | WNK3 | 20.9% | 79.1% |
| 4 | IKKE_IKBKE | 17.9% | 82.1% |
| 5 | SGK2 | 16.2% | 83.8% |
| 6 | ERK1 | 14.3% | 85.7% |
| 7 | PLK3 | 13.2% | 86.8% |
| 8 | PAK5 | 12.2% | 87.8% |
| 9 | MLK3_MAP3K11 | 12.1% | 87.9% |
| 10 | CDK9_CYCLIN_K | 12.0% | 88.0% |
| 11 | RIPK4 | 12.0% | 88.0% |
| 12 | P38G | 11.7% | 88.3% |
| 13 | MST4 | 11.6% | 88.4% |
| 14 | P38D_MAPK13 | 11.6% | 88.4% |
| 15 | PDK2_PDHK2 | 11.5% | 88.5% |
| 16 | ALK2_ACVR1 | 11.1% | 88.9% |
| 17 | ERK5_MAPK7 | 10.7% | 89.3% |
| 18 | CAMK1A | 10.7% | 89.3% |
| 19 | CAMKK1 | 10.4% | 89.6% |
| 20 | CDK4_CYCLIN_D3 | 10.4% | 89.6% |
Selectivity landscape
Where Inavolisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Inavolisib.
Annotations
Sign in to read and post annotations.
Loading…